OP64F Sigma-AldrichAnti-p21WAF1 (58-77) (Ab-1) Mouse mAb (EA10) Fluorescein Conjugate
Produits recommandés
Aperçu
Replacement Information |
---|
Tableau de caractéristiques principal
Species Reactivity | Host | Antibody Type |
---|---|---|
H | M | Monoclonal Antibody |
Product Information | |
---|---|
Form | Liquid |
Formulation | In 50 mM sodium phosphate buffer, 50% glycerol. |
Negative control | Unstimulated cells, unstimulated skin tissue, or SK-OV-3 cells |
Positive control | Any cell line expressing wild-type p53 (e.g. Hs27 cells or U2OS cells treated with DNA damaging agents) or UV-treated skin or colon tissue |
Preservative | None |
Quality Level | MQ100 |
Physicochemical Information |
---|
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information |
---|
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Référence | GTIN |
OP64F | 0 |
Documentation
Anti-p21WAF1 (58-77) (Ab-1) Mouse mAb (EA10) Fluorescein Conjugate FDS
Titre |
---|
Anti-p21WAF1 (58-77) (Ab-1) Mouse mAb (EA10) Fluorescein Conjugate Certificats d'analyse
Titre | Numéro de lot |
---|---|
OP64F |
Références bibliographiques
Aperçu de la référence bibliographique |
---|
Agarwal, M.L., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 8493. Chen, Y.Q., et al. 1995. Int. J. Oncology 7, 889. Deng, C., et al. 1995. Cell 82, 675. Waldman, T., et al. 1995. Cancer Res. 55, 5187. Elbendary, A., et al.1994. Cell Growth Diff. 5, 1301. El-Deiry, W.S., et al. 1994 Cancer Res. 54, 1169. Li, R., et al. 1994. Nature 371, 534. Michieli, P., et al. 1994. Cancer Res. 54, 3391. Noda, A., et al.1994. Exp. Cell Res. 211, 90. El-Deiry, W.S., et al.1993. Cell 75, 817. Gu, Y., et al. 1993. Nature 366, 707. Harper, J.W., et al.1993. Cell 75, 805. Xiong, Y., et al.1993. Genes Devel. 7, 1572. Xiong, Y., et al.1993. Nature 366, 701. Xiong, Y., et al.1992. Cell 71, 505. |